Operating Expenses
Stock-Based Compensation Expense
Vertex Pharmaceuticals Stock-Based Compensation Expense increased by 5.6% to $166.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.2%, from $166.10M to $166.40M. Over 4 years (FY 2021 to FY 2025), Stock-Based Compensation Expense shows an upward trend with a 11.6% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID:
adi_stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.60M | $103.00M | $118.60M | $130.30M | $113.90M | $135.60M | $111.50M | $145.30M | $145.30M | $145.30M | $145.30M | $191.90M | $154.20M | $184.60M | $167.80M | $166.10M | $167.30M | $194.90M | $157.60M | $166.40M |
| QoQ Change | — | -1.5% | +15.1% | +9.9% | -12.6% | +19.1% | -17.8% | +30.3% | +0.0% | +0.0% | +0.0% | +32.1% | -19.6% | +19.7% | -9.1% | -1.0% | +0.7% | +16.5% | -19.1% | +5.6% |
| YoY Change | — | — | — | — | +8.9% | +31.7% | -6.0% | +11.5% | +27.6% | +7.2% | +30.3% | +32.1% | +6.1% | +27.0% | +15.5% | -13.4% | +8.5% | +5.6% | -6.1% | +0.2% |
Range$103.00M – $194.90M
CAGR+10.3%
Avg YoY Growth+11.7%
Median YoY Growth+8.7%
Stock-Based Compensation Expense at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's stock-based compensation expense?
- Vertex Pharmaceuticals (VRTX) reported stock-based compensation expense of $166.40M in Q1 2026.
- How has Vertex Pharmaceuticals's stock-based compensation expense changed year-over-year?
- Vertex Pharmaceuticals's stock-based compensation expense increased by 0.2% year-over-year, from $166.10M to $166.40M.
- What is the long-term trend for Vertex Pharmaceuticals's stock-based compensation expense?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's stock-based compensation expense has grown at a 11.6% compound annual growth rate (CAGR), from $441.40M to $685.90M.